The Australasian Psoriasis Collaboration view on methotrexate for psoriasis in the Australasian setting.

@article{Rademaker2017TheAP,
  title={The Australasian Psoriasis Collaboration view on methotrexate for psoriasis in the Australasian setting.},
  author={Marius Rademaker and Monisha Das Gupta and Megan E. Andrews and Katherine S Armour and Chris Baker and Peter Foley and Kurt Gebauer and Jacob George and Diana M Rubel and John R. Sullivan},
  journal={The Australasian journal of dermatology},
  year={2017},
  volume={58 3},
  pages={
          166-170
        }
}
The Australasian Psoriasis Collaboration reviewed methotrexate (MTX) in the management of psoriasis in the Australian and New Zealand setting. The following comments are based on expert opinion and a literature review. Low-dose MTX (< 0.4 mg/kg per week) has a slow onset of action and has moderate to good efficacy, together with an acceptable safety profile. The mechanism of action is anti-inflammatory, rather than immunosuppressive. For pretreatment, consider testing full blood count (FBC… CONTINUE READING
1
Twitter Mention